Abstract
Purpose: There is growing interest in delivery of drugs and radioisotopes with carriers designed to target molecular receptors in the vascular space. In contrast to targets outside of blood vessels, vascular receptors are easily accessed and tracer binding is not significantly impacted by the size of the targeted drug carrier. Although it is accepted that vascular targeting is very efficient, the kinetics of target binding in the vascular space immediately after injection has not been evaluated. MAb 201B accumulation in mouse lung, by virtue of its binding to thrombomodulin on lung endothelium, has been used as a model for imaging and vascular targeting. Procedures: MAb 201B was radioiodinated with either 125I comparing two different methods of radioiodination to assess label stability. MAb accumulation and retention were monitored after iv injection in normal BALB/c mice by standard biodistribution experiments, SPECT/CT. MAb radiolabeled with positron emitting 124I was evaluated by dynamic microPET. Results: The data show that lung uptake and kinetics of loss (t1/2∼40 hrs) of 125I MAb 201B was similar with two different radio-iodination methods. Loss of radioiodine was detected in sample radiolabeled using the chloramine T method, but only at later time points (24hrs). For very short time evaluations the more efficient chloramine T method was adopted for PET studies with 124I. Lung uptake of 124I MAb 201B occurred within seconds of injection as observed in dynamic microPET analysis with little 124I MAb ever detected in the peripheral circulation. In contrast, distribution kinetics of control 124I MAb 14 or 124I MAb 201B that had been diluted with excess cold MAb demonstrated equilibration throughout the vascular space. CONCLUSION: Accumulation of MAb targeted to epitopes in the vascular space occurs very rapidly, is highly specific and very efficient. Drug delivery with vascular targeting agents can accommodate fast acting therapeutic agents including short half lived radioisotopes
Keywords: SPECT/CT, dynamic PET, vascular targeting, 124I Mab, thrombomodulin
Current Drug Delivery
Title: Kinetics of Vascular Targeted Monoclonal Antibody
Volume: 7 Issue: 5
Author(s): Stephen J. Kennel, Ying Huang, Wen- Bin Zeng, Alan Stuckey and Jonathan Wall
Affiliation:
Keywords: SPECT/CT, dynamic PET, vascular targeting, 124I Mab, thrombomodulin
Abstract: Purpose: There is growing interest in delivery of drugs and radioisotopes with carriers designed to target molecular receptors in the vascular space. In contrast to targets outside of blood vessels, vascular receptors are easily accessed and tracer binding is not significantly impacted by the size of the targeted drug carrier. Although it is accepted that vascular targeting is very efficient, the kinetics of target binding in the vascular space immediately after injection has not been evaluated. MAb 201B accumulation in mouse lung, by virtue of its binding to thrombomodulin on lung endothelium, has been used as a model for imaging and vascular targeting. Procedures: MAb 201B was radioiodinated with either 125I comparing two different methods of radioiodination to assess label stability. MAb accumulation and retention were monitored after iv injection in normal BALB/c mice by standard biodistribution experiments, SPECT/CT. MAb radiolabeled with positron emitting 124I was evaluated by dynamic microPET. Results: The data show that lung uptake and kinetics of loss (t1/2∼40 hrs) of 125I MAb 201B was similar with two different radio-iodination methods. Loss of radioiodine was detected in sample radiolabeled using the chloramine T method, but only at later time points (24hrs). For very short time evaluations the more efficient chloramine T method was adopted for PET studies with 124I. Lung uptake of 124I MAb 201B occurred within seconds of injection as observed in dynamic microPET analysis with little 124I MAb ever detected in the peripheral circulation. In contrast, distribution kinetics of control 124I MAb 14 or 124I MAb 201B that had been diluted with excess cold MAb demonstrated equilibration throughout the vascular space. CONCLUSION: Accumulation of MAb targeted to epitopes in the vascular space occurs very rapidly, is highly specific and very efficient. Drug delivery with vascular targeting agents can accommodate fast acting therapeutic agents including short half lived radioisotopes
Export Options
About this article
Cite this article as:
J. Kennel Stephen, Huang Ying, Bin Zeng Wen-, Stuckey Alan and Wall Jonathan, Kinetics of Vascular Targeted Monoclonal Antibody, Current Drug Delivery 2010; 7 (5) . https://dx.doi.org/10.2174/156720110793566227
DOI https://dx.doi.org/10.2174/156720110793566227 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prospects of Embryonic Stem Cells in Treatment of Hematopoietic Disorders
Current Pharmaceutical Biotechnology Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Prospectives for Gene Therapy of Retinal Degenerations
Current Genomics Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism Recent Advances in Understanding of Kinetic Interplay Between Phase II Metabolism and Efflux Transport
Current Drug Metabolism The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Survey of Computational Algorithms for MicroRNA Target Prediction
Current Genomics APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets An Illustrative Review of Solid Pancreatic Masses: Differential Diagnostic Features of CT and MRI Findings
Current Medical Imaging Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update
Medicinal Chemistry Reviews - Online (Discontinued) The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets